| Diabetes Mellitus, Non-Insulin-Dependent
Atorvaliq vs Basaglar
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Atorvaliq vs Basaglar with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBasaglar has a higher rate of injection site reactions vs Atorvaliq based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Basaglar but not Atorvaliq, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Atorvaliq
Basaglar
At A Glance
Oral
Daily
HMG-CoA reductase inhibitor
SC injection
Once daily
Long-acting insulin analog
Indications
- Coronary heart disease
- Diabetes Mellitus, Non-Insulin-Dependent
- Heart failure
- Hyperlipidemia
- Hypercholesterolemia, Familial
- Hypertriglyceridemia
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Coronary heart disease, Diabetes Mellitus Non-Insulin-Dependent, Heart failure, Hyperlipidemia, Hypertriglyceridemia 10 or 20 mg once daily orally on an empty stomach; dosage range 10-80 mg once daily; patients requiring LDL-C reduction >45% may start at 40 mg once daily.
Hypercholesterolemia, Familial (HeFH, pediatric >= 10 years) 10 mg once daily orally on an empty stomach; dosage range 10-20 mg once daily.
Hypercholesterolemia, Familial (HoFH, pediatric >= 10 years) 10-20 mg once daily orally on an empty stomach; dosage range 10-80 mg once daily.
Type 1 Diabetes Mellitus Approximately one-third of total daily insulin requirements SC once daily; short- or rapid-acting pre-meal insulin covers the remainder.
Diabetes Mellitus, Non-Insulin-Dependent 0.2 units/kg or up to 10 units SC once daily.
Contraindications
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to atorvastatin or any excipients in ATORVALIQ
- Episodes of hypoglycemia
- Hypersensitivity to insulin glargine or any excipient in BASAGLAR
Adverse Reactions
Most common (>=2%) Nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain
Serious Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Pancreatitis, fatigue, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, rhabdomyolysis, myositis, dizziness, peripheral neuropathy, cognitive impairment, depression, interstitial lung disease, angioneurotic edema, bullous rashes
Most common (>=5%) Infection, nasopharyngitis, upper respiratory tract infection
Serious Severe hypoglycemia, anaphylaxis, peripheral edema, lipodystrophy, localized cutaneous amyloidosis
Postmarketing Medication errors (accidental administration of rapid-acting insulin instead of insulin glargine), localized cutaneous amyloidosis, hyperglycemia or hypoglycemia associated with injection site changes
Pharmacology
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a cholesterol precursor; it lowers plasma cholesterol and LDL levels by inhibiting hepatic cholesterol synthesis and increasing hepatic LDL receptor expression.
Insulin glargine is a long-acting human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production, providing sustained glucose-lowering activity over 24 hours with no pronounced peak.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
No coverage data available for Atorvaliq.
Basaglar
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (6/12) · Qty limit (0/12)
UnitedHealthcare
No coverage data available for Atorvaliq.
Basaglar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
No coverage data available for Atorvaliq.
Basaglar
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Atorvaliq.
No savings programs available for Basaglar.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AtorvaliqView full Atorvaliq profile
BasaglarView full Basaglar profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.